Evommune, Inc. EVMN
7.65 USD +1.00 (+15.04%)
At closeNov 9, 2026, 4:00 PM EST
7.65 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
6.73 Day range 7.87
4.94 52-week range 33.20
- YTD
- -55.32%
- 1 year
- -58.45%
- Market cap
- 277.63M
- EPS (ttm)
- -3.75
- YTD return
- -55.32%
- 1-year return
- -58.45%
- Volume
- 823.67K
- Avg volume
- 777.63K
- Open
- 6.82
- Previous close
- 6.65
- Day's range
- 6.73 – 7.87
- 52-week range
- 4.94 – 33.20
5D -0.15 (-2.21%)
Financials — quick view
EVMN Revenue — quarterly 0
EVMN Net income — quarterly -32.25M
EVMN EPS — quarterly -0.89
News
Evommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund Development 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET 
Evommune Announces $30 Million Private Placement 
Evommune Receives Exclusive License From Hinova Pharmaceuticals To Develop, Manufacture, Commercialize EVO570 Outside China; Hinova To Get $30M Upfront Payment 
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
UBS Initiates Coverage On Evommune with Neutral Rating, Announces Price Target of $8 
Evommune Presents Additional Data From Phase 2a Proof-Of-Concept Trial Of EVO301 In Adults With Atopic Dermatitis At EADV 2026 Congress; Plan To Initiate Subcutaneous Phase 2b Dose-Ranging Trial In Mid-2027 
Evommune To Present Results From Phase 2a Study Of EVO301 In Moderate-To-Severe Atopic Dermatitis At European Academy Of Dermatology & Venereology Congress
Your note
Sign in to keep a note on EVMN — it syncs with the Stock Master app.